Info
Combining world-leading scientific and medical expertise with cutting-edge technical innovation, to improve diagnostic accuracy and enhance clinical care for cancer patients.
Accurate and precise diagnosis is crucial for optimal management of patients with cancer. Epignostix vision is to help create a world in which all cancer patients are treated appropriately and as individuals, by providing innovative solutions for precision molecular diagnostics.
The company has developed its expertise since its establishment in 2022, building on decades of combined experience of its founders. Epignostix conduct research and development, certification and marketing of software solutions for molecular tumour classification based on DNA methylation profiling and machine learning.